Given the clinical relevance of GPC1 expression in NSCLC, this study was focused on evaluating the effect of a new anti-GPC1 mAb on lung tumor growth using in vitro and in vivo models and exploring the associated mechanisms. Here, GPC1 is linked to non-small cell lung carcinoma.